Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese
 subjects that have a sudden worsening of their symptoms of schizophrenia. The study will also
 assess the efficacy of vabicaserin and compare it to risperidone.
Inclusion Criteria:

 -  Male and female subjects between >=20 and =<65 years of age

 -  Current diagnosis and DSM-IV-TR diagnosis of schizophrenia type (295.10, 295.30 and
 295.90)

 -  Total PANSS score >=70 and =< 120

 Exclusion Criteria:

 -  Subjects who are hospitalized against their will

 -  Current Axis I primary psychiatric diagnosis other than schizophrenia

 -  A score of 3 on CDSS question 8 which pertains to suicide